Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study
Titel:
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study
Auteur:
Pivot, X. Spano, J.P. Espie, M. Cottu, P. Jouannaud, C. Pottier, V. Moreau, L. Extra, J.M. Lortholary, A. Rivera, P. Spaeth, D. Attar-Rabia, H. Benkanoun, C. Dima-Martinez, L. Esposito, N. Gligorov, J.